Q32 Bio Inc. (QTTB): M&A transaction — Q32 Bio sells complement inhibitor ADX-097 to Akebia for up to $592M total consideration

Q32 Bio Inc.

Upfront and guaranteed near-term payments of $12M ($7M at closing, $3M at 6 months, $2M milestone).
Eligible for up to $92.5M in development/regulatory milestones and $487.5M commercial milestones.
Tiered royalties on future sales of ADX-097 from low single-digit to mid-teen percent.
Cash runway extended into H2 2027; topline SIGNAL-AA Part B data expected mid-2026.
Q32 retains tissue-targeted complement platform including ADX-096; evaluating strategic options.

item 1.01 item 1.02 item 2.01 item 7.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Q32 Bio Inc. completed a disposition involving Akebia Therapeutics, Inc. for $7.0 million upfront (closed 2025-11-28).

Action: disposition
Counterparty: Akebia Therapeutics, Inc.
Consideration: $7.0 million upfront
Closing: 2025-11-28

Exact text from the filing

will be responsible for any future development and commercialization of ADX-097. As consideration for the ADX-097 Asset Sale, the Company (i) received an upfront payment of $7.0 million on the Closing Date, and (ii) will receive a payment of $3.0 million on the six-month anniversary of the Closing Date. The Company will also receive a near-term milestone payment

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Q32 Bio Inc. entered into Asset Purchase Agreement with Akebia Therapeutics, Inc. valued at upfront payment of $7.0 million, payment of $3.0 million, milestone payment of $2.0 million, up to $ (effective 2025-11-28).

Action: entry
Agreement: asset purchase
Counterparty: Akebia Therapeutics, Inc.
Value: upfront payment of $7.0 million, payment of $3.0 million, milestone payment of $2.0 million, up to $
Effective: 2025-11-28

Exact text from the filing

On November 28, 2025 (the “Closing Date”), Q32 Bio Inc. (the “Company”), entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”) with Q32 Bio Operations Inc., a wholly-owned subsidiary of the Company (“Q32 Bio Operations” and, together with the Company, the “Seller”), and Akebia Therapeutics, Inc. (“Akebia”)

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Q32 Bio Inc. terminated Colorado License Agreement with The Regents of the University of Colorado (effective 2025-11-28).

Action: termination
Agreement: license
Counterparty: The Regents of the University of Colorado
Effective: 2025-11-28

Exact text from the filing

On November 28, 2025, in connection with the ADX-097 Asset Sale, the Company terminated its obligations under that certain exclusive license agreement, dated August 9, 2017, as amended in February 2018, September 2018, and April 2019 (the “Colorado License Agreement”), with The Regents of the University of Colorado

View on SEC.gov

Browse all m&a transactions →

Q32 Bio Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-303115

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.